B vitamins are usually functioning as a precursor of coenzymes and prosthetic groups of enzymes. For example, TPP, FMN and so on.These vitamins are essential for cell functions, several physiological events, and in the metabolism of various neurotransmitters and neurohormones such as serotonin, dopamine, acetylcholine etcCertain B vitamin support nerve regeneration process (B1,B6 and B12. These vitamins are common called NEUROTROPHIC B vitamins, which constantly protect nerves against damaging environmental influences.B12 helps in promoting functional recovery, axonal regeneration, attenuate edema and myelin sheath regeneration after sciatic injury. B6 helps in balancing nerve metabolism and,B1 acts as a site-directed antioxidant.

The discovery may lead to development of drugs that halt disease progression and stop memory loss
According to research funded by the British Heart Foundation, a breakthrough in understanding Alzheimer’s disease has revealed changes to blood vessels in the brain, potentially presenting a path for developing new drugs to help fight the disease.
Alzheimer’s disease is traditionally thought of as a disease of the brain cells, where the protein Amyloid-beta (Aβ) accumulates and forms plaques. There is growing evidence, however, that the blood supply to the brain is also affected.
Researchers at the University of Manchester have found that a smaller version of the protein – called Amyloid-β 1-40 (Aβ 1-40) – builds up in the walls of the small arteries and reduces blood flow to the brain.
The surface of the brain is covered with small pial arteries which control the brain’s supply of blood and oxygen. If these arteries become narrowed for too long, the brain can’t get enough nutrients and this is one of the causes of memory loss seen in people with the disease.
When the team looked at pial arteries of older mice with Alzheimer’s that produced too much Aβ1-40, they found that the arteries were narrower compared to those of healthy mice. This narrowing was found to be caused by Aβ 1-40 switching off a protein known as BK which, when working normally, sends a signal which causes arteries to widen.
Read more: https://www.pharmatimes.com/news/blood_vessel_breakthrough_is_major_step_towards_alzheimers_treatment_1450211

I'm a specialist Life Sciences insurance consultant.  Happy to provide impartial complimentary advise to businesses that might require a helpful chat!?

HPLC, LC-MS/MSHPLC, LC-MS/MS

Omri Shor, Co-founder & CEO of Medisafe, sat down with me for an in-depth discussion around the role of digital therapeutics in advancing and supporting the patient journey. Among many other things, we explored how new digital health tools are driving deeper engagement for patients and why personalization of the patient journey is essential (and how to achieve it).

Earlene Biggs, VP of Market Research & Analytics at ICON, sat down with me to discuss best practices for life science market research and actionable analytics. She also shared her tips for creating organizational wellbeing and inclusiveness, plus much more.

‘Act4Biosimilars’ will improve patient access and increase adoption in over 30 countries by 2030
Biosimilar company Sandoz has announced the launch of a new global initiative to take on worldwide health inequities.
Act4Biosimilars aims to increase patient access to advanced medicines by leveraging the ‘4 As’ of biosimilars – approvability, accessibility, acceptability and affordability. The initiative is supported by a multidisciplinary steering committee of patient advocacy leaders, healthcare professionals, biosimilar experts and industry leaders from across the world.
Other notable targets of the project include ensuring equitable pricing, involving patients in treatment decisions and streamlining biosimilar development. The ultimate goal is to increase global adoption of biosimilar medicines by at least 30% throughout 30 countries by 2030.
Read more: https://www.pharmatimes.com/news/sandoz_launches_new_global_health_inequalities_initiative_1449438

A version of this article was previously published on PharmaPhorum.
Trust in life science companies has fluctuated since the start of the pandemic. The reputation of COVID-19 vaccine makers understandably soared early on, as clinical trials were started and completed in record time, giving hopes to millions of people in lockdown. Since then, inconsistent messaging around the need for booster shots, as well as side effects–no matter how rare–have tarnished their name. Likewise, trust in the overall health sector is currently 2 percentage points below January 2020 levels, and far below (11 percentage points) May 2021 levels. One survey puts the percentage of persons with trust in the pharmaceutical industry in 2021 at only 50% in the UK and Canada, with the corresponding percentage in the US being even lower, at 47%. India currently has the highest percentage of trust, at 80%. Read the full blog article here: https://www.impetusdigital.com/2022/05/10/trust-and-transparency-in-pharma/

A-Tek Pharma are a UK MHRA licensed pharmaceutical wholesaler. We hold a strong position at our UK base in Bristol, as well as trading across Europe and the International markets, providing our valued customers with our UK partnered manufactured and branded pharmaceutical medicines. 

Gifford is supporting the launch with a philanthropic donation of £14.7m
A new multi-million-pound pandemic science hub is being created, to develop treatments for lung infections such as COVID-19 and prepare the UK for similar future pandemics.
The research programme was announced at the University of Edinburgh, with support from a significant donation from Baillie Gifford.
The programme – called The Baillie Gifford Pandemic Science Hub – will use translational genomics with experimental medicine methods, to quickly evaluate and develop drugs for lung inflammation, and injury caused by infection.
The hub builds on the success of GenOMICC – a global research study that aims to understand the genetic factors that change outcomes in critical illness – and STOPCOVID. GenOMICC recently discovered a further 16 genes underlying severe COVID-19, potentially leading to even more effective treatments.
Read more:https://www.pharmatimes.com/news/the_baillie_gifford_pandemic_science_hub_launched_to_fight_lung_disease_1448634

BioXcel Therapeutics has announced that the first patient involved in the phase 3 TRANQUILITY 2 study of BXCL501 has received a dose for the acute treatment of agitation in patients with Alzheimer’s disease.
BXCL501 – the company’s orally dissolving, thin film formulation of dexmedetomidine – has been assessed as part of a pivotal phase 3 TRANQUILITY programme.
The programme began in December 2021 and is made up of two studies, TRANQUILITY 2 and TRANQUILITY 3.
Each study has been designed to evaluate the safety and effectiveness of BXCL501 in adults aged 65 years and older who are in assisted living, residential facilities or nursing homes.
Alzheimer’s disease is the most common form of dementia in the US, and it is expected that by 2040, approximately 12 million Americans aged 65 years and over may be impacted by the disease. Of these patients, up to 70% experience agitation, while around 100 million agitation episodes happen in the US annually. The knock-on effect of these episodes on both patients and their caregivers can be devastating.
As yet, there are no approved therapeutic options available for the acute treatment of agitation related to dementia, including Alzheimer’s disease.
https://www.pmlive.com/pharma_news/bioxcel_therapeutics_begins_phase_3_trial_for_acute_agitation_in_alzheimers_patients_1447890

Happy to share our new platform with all the professionals.
MediHeroes is a cross-border B2B medical platform that connects suppliers, service providers, distributors, and all the stakeholders in the MedTech Industry. From Search to Match, MediHeroes members can save years in finding quality medical supplies & services and global communities across the countries.
Join now and enjoy a 90-Day free trial!

I haven't had much respose to the ask for the an interview, I thought it would be best to share the interactive demo so it would become more appartent what we are doing at Filestage
https://myinteractive.video/w/mIEKgXVW

Hi,
My company Filestage helps Pharma & BioTech companies review their marketing and sales materials quicker and more accurately. I am looking for a few people in the industry to help us further understand the needs of the marketing teams. Please reach out to our Head of Marketing nick.stein@filestage.io if you would like to have a chat.
https://filestage.io/pharma-and-biotech/?utm_source=Social&utm_medium=post&utm_id=pharmaemed
To get a hands-on experience of the platform, try our interactive demo - https://myinteractive.video/w/mIEKgXVW 

A version of this article was previously published in the Journal of mHealth.
With our growing dependence on social media over the past decade, Digital Opinion Leaders–or “DOLs” for short–are becoming an increasingly important stakeholder group for Pharma teams to engage and consult. But who are these DOLs, and why and how should Pharma companies leverage them? Read the full blog article below.